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Abstract
Background: Non-coding RNAs have critical functions in diverse biological processes, particularly in gene regulation.
Viruses, like their host cells, employ such functional RNAs and the human cancer associated Epstein-Barr virus (EBV) is no
exception. Nearly all EBV associated tumours express the EBV small, non-coding RNAs (EBERs) 1 and 2, however their role in
viral pathogenesis remains largely obscure.
Methodology/Principal Findings: To investigate the action of EBER1 in vivo, we produced ten transgenic mouse lines
expressing EBER1 in the lymphoid compartment using the mouse immunoglobulin heavy chain intronic enhancer Em. Mice
of several of these EmEBER1 lines developed lymphoid hyperplasia which in some cases proceeded to B cell malignancy. The
hallmark of the transgenic phenotype is enlargement of the spleen and mesenteric lymph nodes and in some cases
enlargement of the thymus, liver and peripheral lymph nodes. The tumours were found to be of B cell origin and showed
clonal IgH rearrangements. In order to explore if EBER1 would cooperate with c-Myc (deregulated in Burkitt’s lymphoma) to
accelerate lymphomagenesis, a cross-breeding study was undertaken with EmEBER1 and EmMyc mice. While no significant
reduction in latency to lymphoma onset was observed in bi-transgenic mice, c-Myc induction was detected in some
EmEBER1 single transgenic tumours, indicative of a functional cooperation.
Conclusions/Significance: This study is the first to describe the in vivo expression of a polymerase III, non-coding viral gene
and demonstrate its oncogenic potential. The data suggest that EBER1 plays an oncogenic role in EBV associated malignant
disease.
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Introduction
Epstein-Barr virus (EBV) is a common human gamma-
Herpesvirus infecting more than 90% of the world-wide
population. It is normally contracted asymptomatically at an
early age via saliva, persisting as a life-long infection in a latent
state. If contracted post-puberty it can result in infectious
mononucleosis, usually a self-limiting disease. However, EBV is
also associated with several malignancies including Burkitt’s
lymphoma (BL), Hodgkin’s disease and nasopharyngeal carcino-
ma [1]. In BL, EBV expression is restricted to the nuclear antigen
1 (EBNA1), the EBV encoded small RNAs (EBER1 and EBER2)
and BART microRNAs (miRNAs) [2]; this limited expression
pattern facilitates viral evasion of host immune defences. BL is
also characterised by overexpression of c-Myc resulting from
translocation of the gene to an immunoglobulin locus.
EBER1 and EBER2 (167 and 172 nucleotides, respectively) are
RNA polymerase (pol) III transcripts and are highly conserved
amongst EBV strains [3–5]. The secondary structures of the
EBERs are predicted to include extensive double stranded regions
with a number of short stem loops [3,6]. These structures are
conserved in the homologous Papio (baboon) Herpesvirus RNAs
(HVP-1 and -2) [7], suggesting that they are critical for the EBERs
interaction with specific proteins and their function. Several
proteins bind to the EBERs, including double-stranded RNA-
activated protein kinase (PKR), La antigen, ribosomal protein
L22, 29-59 oligoadenylate synthetase, EBNA1 and retinoic acid-
inducible gene I (RIG-I) [8–10].
The EBERs are hypothesised to disrupt the host cell interferon
response, but this role is currently ambiguous. They can stimulate
type I interferon (IFN) through recognition by the dsRNA binding
protein RIG-I [10]. Conversely, EBER1 was shown to inhibit
IFNa induced apoptosis and a suggested mechanism for this is
through binding to PKR thereby inhibiting PKR auto-phosphor-
ylation and thus blockade of downstream events [11], however,
this proposed mechanism has been questioned [12]. Ruf et al.
observed no differences in the levels of phosphorylated PKR or its
substrate following IFNa treatment of EBV positive and negative
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cells, leaving the mechanism by which the EBERs mediate
resistance to IFNa-induced apoptosis currently unresolved. These
observations are further complicated by the finding that in
trafficking assays EBER1 appears to be confined to the nucleus
[13] while PKR and RIG-I are largely cytosolic.
The EBERs are expressed in virtually all EBV associated
tumours and are the most abundant viral transcripts in several
latently infected B-cell lines [14]. Their ready detection allows
them to be used as indicators for the presence of EBV in infected
cells by in situ hybridisation [15]. A potential role of the EBERs in
malignant pathogenesis was suggested by the observation that they
can render lymphoma cells more malignant and protect them
from some apoptosis inducing agents, such as IFNa [16-19].
Furthermore, the EBERs promote the induction of autocrine
growth factors interleukin (IL)-10, IL-9 and insulin-like growth
factor-1 [20–22]. A functional difference between the EBERs has
been described, where EBER2 but not EBER1 was found to
promote EBV mediated B-cell immortalisation in vitro, at least in
part through IL-6 induction [23] and an EBER2 specific analysis
of changes in cellular expression has been conducted [24].
However, for most studies the role of the two EBERs has not
been separated and thus their individual functions remain elusive.
In addition, prior to the study described here, there has been no
animal model for analysing the function and mechanisms of the
EBERs in vivo.
To investigate the independent role of EBER1, we have
generated transgenic mice expressing EBER1 in the lymphoid
compartment using its viral pol II/pol III promoter and included a
cellular lymphocyte specific pol II enhancer. Several lines of
EBER1 mice developed lymphoid hyperplasia and in some cases B
cell lymphoma. In order to model the situation in BL, EBER1
expressing mice were then cross-bred with transgenic lines
expressing either c-Myc or EBNA1, or N-Myc as a further
comparison, and latency to lymphoma was examined.
Results
Generation of EBER1 Transgenic Mice
To explore a potential EBER1 induced lymphoid phenotype in
vivo, transgenic mice were generated designed to express EBER1 in
the lymphoid compartment. The natural viral transcriptional
control unit of EBER1 is composed of a hybrid of classical RNA
pol II and pol III motifs. The 59 promoter incorporates two pol II
motifs (Sp1 and ATF binding sites) upstream of a TATA-like box
(TGTA). Further upstream, two E-boxes were identified and
provide c-Myc binding sites [25]. Within the transcription unit are
‘‘A’’ and ‘‘B’’ boxes typical of type II pol III promoters [26]. In
order to attempt to restrict expression to the lymphoid
compartment, the pol II murine immunoglobulin heavy chain
(IgH) intronic enhancer (Em) was placed at the 59 end of three
constructs, with progressive deletion of the EBER1 promoter
(Figure 1). The competence to express EBER1 from the three
constructs was confirmed by quantitative (q)RT-PCR and
northern blotting following transient transfection into a murine
B-cell line (data not shown).
Nineteen transgenic mouse founders were generated with the
EmEBER1 constructs, from which 13 lines were established
(supplementary Table S1). The integrated transgene head-to-tail
tandem copy number was estimated by slot blot from 1st
generation offspring and ranged from 2 to approximately 200
(supplementary Table S1). Lines 127 (Em78EBER1) and 138
(Em39EBER1) demonstrated an X-linked pattern of inheritance
with all others being autosomal (not shown).
Ten out of eleven lines assessed for transgene expression showed
EBER1 expression in at least one lymphoid tissue (Figure 2). The
expression pattern in the lymphoid tissues differs between lines; for
instance line 127 expresses EBER1 to varying degrees in the
lymphoid tissues with Peyer’s patches (PP) showing highest
expression, whereas line 131 shows relatively equal expression
levels across the lymphoid tissues. A comparative expression
analysis (by quantitative RT-PCR) was conducted between
samples from different lines and compared to the Akata EBV
positive B-cell line (supplementary Figure S1). This showed that
for Peyer’s patches samples the levels of EBER1 expression
(highest first) was lines 127, then 131, 142, 137, 136 and for
thymus the order was 142, 127, 131, 137, 136. The level of
EBER1 transcript detected in the tissues was three orders of
magnitude lower than that quantified in the clonal Akata BL cell
line. Cells of the spleen and Peyer’s patches of the highest
expressing line (line 127) were separated into B-cell and T-cell
fractions, revealing EBER1 expression in both populations (shown
for Peyer’s patches, Figure 3B). However, line 134 shows almost
exclusive expression to the spleen and 137 to the thymus (Figure 2)
which would suggest B-cell and T-cell specific expression in these
two lines (respectively). Expression in non-lymphoid tissues was
also examined in lines 127, 131, 136 and 137 (supplementary
Figure S2). Line 127 showed no expression in other tissues with the
exception of the brain, whereas line 131 showed expression in
several non-lymphoid tissues.
The expression patterns and levels show no correlation with the
transgene copy number (as is usual), or with the three different
constructs used and are likely to be influenced by the chromatin
configuration at the sites of transgene insertion. Efficient
transcription of the EBER genes has previously been shown to
require the native upstream pol II elements (ATF, Sp1 and E-
boxes) [5]. These elements have been completely deleted from the
Figure 1. The EnEBER1 transgenes. The Em cassette (white box) was placed 59 of three EBER1 EcoRI-XhoI gene fragments which include promoter
sequences from 2323, 278 or 239 from the canonical start of EBER1 transcription. EBER1 promoter motifs: E-box, Sp1 and ATF binding sites and
TGTA box are indicated. All constructs include the EBER1 transcription unit (black) with pol III ‘‘A’’ and ‘‘B’’ boxes.
doi:10.1371/journal.pone.0009092.g001
EBER1 Transgenic Mice
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Em39EBER1 construct used here, which nevertheless shows
expression at comparable levels to the transgenes retaining these
elements (Em78EBER1 and Em323EBER1) (Figure 2 and supple-
mentary Figure S1). Therefore deletion of the native EBER1
promoter pol II elements appears to have been compensated for
by the inclusion of the Em element (which incorporates E-boxes).
Lymphoid restricted expression was achieved in some lines,
notably in lines 134 and 137 with the Em39EBER1 transgene,
suggesting that deletion of the EBER1 Sp1 and ATF elements may
have achieved this restriction in some cases.
Figure 2. EBER1 expression pattern in mouse lymphoid tissues. Transgene expression was examined in mice of Em78EBER1 lines and a
transgene-negative sibling control (NSC) (A), Em323EBER1 lines (B) and Em39EBER1 lines (C) and detected using RNA derived from tissues of 2 to 4
month old mice by RT-PCR using a gene specific RT primer (CR4). PCR (CR8/CR9) products were Southern blotted and hybridised with an EBER1
probe. Data for lymphoid tissues are shown, including spleen (S), thymus (T), bone marrow (BM), peripheral lymph nodes (PLN), mesenteric lymph
nodes (MLN), Peyer’s patches (PP) and liver (L). For each RT (+) reaction a no RT (2) control was included. PCR controls included a water only negative
(N) control and a plasmid DNA amplified positive (P) control. Quality and quantity of all RNAs analysed was assessed and controlled for by RT-PCR for
GAPDH, using oligodT for the RT reaction and GAPDH specific primers.
doi:10.1371/journal.pone.0009092.g002
EBER1 Transgenic Mice
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EBER1 Is Probably Transcribed by Pol III in the Transgenic
Tissues
In order to explore if transgenic EBER1 is transcribed by pol II or
pol III, reverse transcriptase (RT) reactions were performed using the
highest expressing tissues of lines 127, 131, 134, 136 and 137, with
either an EBER1 specific RT primer CR4 (Figures 3A and 3C,
panel i) or an oligodT primer to copy pol II mRNA sequences
(Figure 3C, panel ii). The RT products were amplified by PCR using
EBER1 specific primers (CR8/CR9) and the products quantified
(Figure 3C panel ii). Expression was readily detected using the
EBER1 specific RT primer CR4 (Figure 3C, panel i) with faint signal
detection (0.01 to 0.08 fold compared to CR4) using the oligodT
RT-PCR (Figure 3C, panel ii). These results indicate that the
majority (if not all) of the EBER1 transcripts in these tissues are not
polyadenylated and therefore are unlikely to be transcribed by pol II
using a cryptic or fortuitous cellular polyA addition signal.
An RNA start upstream of the canonical EBER1 start is used to
a minor extent in the transgenic lines 127 and 131 (20% or less) as
was described for the EBV positive BL cell line Raji [27,28]
(Figure 3C, panel iii and 3D, panel v). It was detected using an
upstream PCR primer (CR25) following gene specific RT. The
biological significance of this is unknown, but the longer transcript
could fold differently with functional consequence.
EBER1 Expression Does Not Affect B and T Cell
Proportions in the Lymphoid Tissues of Young
Transgenic Mice
We sought to determine if EBER1 expression in vivo affects
either B and T cell proportions or their differentiation status in the
lymphoid tissues of these mice, prior to the development of any
phenotype. Tissues of young mice of lines 127 and 131 were
examined by flow cytometry. B cells were assessed with B220 and
T cells with CD3 and Thy1.2 markers. No differences were
observed in the proportions of B and T cells in the lymphoid
tissues of lines 127 and 131 (supplementary Figure S3). Lymphoid
expression of several markers for differentiation status were
examined (supplementary Table S5), for line 131 no differences
from controls were observed for any of the lymphoid tissues and
antibodies tested (data not shown), suggesting that for this line the
status of the B and T cells (with respect to the antibodies used) is
not modified by the presence of the transgene. For mice of line
127, the only difference observed between transgenic and
transgene-negative sibling control (NSC) tissues was a possible
perturbation of the longer lived B1a B-cell sub-population in the
Peyer’s patches, the highest expressing tissue of this line
(supplementary Figure S3, panel E). A greater proportion of the
B1a B-cell sub-population in the Peyer’s patches was observed in
the transgenic mice compared to NSC.
The Levels of PKR and eIF2a Phosphorylation Are
Unchanged in EBER1 Transgenic Mice
EBER1 has been shown to inhibit PKR autophosphorylation in
cell free systems [29], however EBER1 shows PKR independent
action in cultured cells [12,30]. To explore if EBER1 expression in
the transgenic mice impacts PKR, steady state levels of PKR and
one of its substrates, the alpha subunit of the eukaryotic initiation
factor 2 (eIF2a) and the activated, phosphorylated forms of both,
were examined in three of the transgenic lines in adult mice prior
Figure 3. Analysis of the transgenic EBER1 transcripts. (A) Schematic diagram of the EBER1 gene showing the canonical start of transcription
(arrow) in relation to the primers used. (B): Cells isolated from Peyer’s patches collected from 3 (pooled) line 127 mice were separated into B and T-
cell fractions and RNA prepared (along with a pre-selection aliquot ‘‘total’’ and Peyer’s patch sample from 3 pooled NSC). EBER1 expression was
assessed by RT-PCR using gene specific RT primer (CR4) and CR8/CR9 PCR. PCR products were Southern blotted and hybridised with an EBER1 probe.
(C and D): RNA from lines 127 (Peyer’s patches), 131 (peripheral lymph nodes), 136 (thymus), 137 (thymus), 134 (spleen) and BL cell lines Raji and
BJAB (EBV positive and negative respectively), was assessed by RT-PCR. The RT reaction was performed using an EBER1 specific primer (CR4) (panels i,
iii, iv and v) or an oligodT primer (panel ii). The RT reaction was followed by PCR using CR8-CR9 primers (panels i, ii and iv) or CR25-CR9 (panels iii and
v). The products were Southern blotted and hybridised with an EBER1 probe. For each RT (+) reaction a no RT (2) control was included. Three
controls were performed for the PCR, a negative (N) water only control and plasmid DNA amplified positive (P) control and routinely oligodT-GAPDH
(not shown) for quality control. The membranes shown in panels i, iii and iv were exposed for 16 hours, whereas ii and v were exposed for 3 days.
Relative signal intensity is given for samples in panels ii and iii compared to i and for panel v compared to iv.
doi:10.1371/journal.pone.0009092.g003
EBER1 Transgenic Mice
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to the development of any phenotype. The highest EBER1
expressing tissue from the three mouse lines; 127, 134 and 137,
namely Peyer’s patches, spleen and thymus, respectively were
assayed compared to NSC tissues. Three biological replicates were
examined in each case and no reduction in steady state or
phosphorylated levels of PKR were observed in the EBER1 tissue
compared with NSC (Figure 4). Similarly no reduction in level or
phosphorylation state of eIF2a was observed for the thymus of 137
and the Peyer’s patches of 127 samples (Figure 4). For line 134
spleen samples, an apparent reduction in the levels of total eIF2a
was detected in the transgenic samples compared to NSC, but no
reduction in phosphorylated eIF2a levels (as a PKR target) was
observed. Splenic samples of line 127 mice did not show this
reduction in total eIF2a levels (not shown) and thus further
characterisation of this observation is required.
EBER1 Transgenic Mice Develop Lymphoid Hyperplasia
and B-Cell Lymphoma
The phenotype of the EBER1 transgenic mice was monitored
alongside NSC. Mice of several lines displayed a pronounced
preneoplastic enlargement of lymphoid tissues, particularly
splenomegaly with lymphoproliferation, also noted in the thymus,
peripheral lymph nodes and Peyer’s patches (Table 1). Lymphoma
was observed in mice of all the lines and the incidence has been
compared to spontaneous lymphoma in NSC (Table 1). A
proportion of NSC mice typically show lymphoid expansion or
develop lymphoma, particularly in the age group over 20 months.
Nevertheless, the incidence of lymphoid expansion or lymphoma
was significantly higher for lines 127, 131, 134 and 135 compared
to NSC.
Subsequent studies of EBER1 transgenic mice were focused on
line 127, as the highest expresser. For line 127, a cohort study over
2 years has been completed, in which 58% (19/33) of the
transgenic mice succumbed to lymphoproliferative disease char-
acterised by extensive pre-neoplastic lymphoid expansion or
lymphoma ranging from 14 to 24 months of age, compared to
23% (35/151) of NSC mice which ranged from 18 and 24 months
(Figure 5). The difference in frequency of this phenotype between
line 127 transgenic and NSC mice is statistically significant
(P,0.0001). The transgenic tumour phenotype typically presented
as a massive enlargement of the spleen and mesenteric lymph
nodes, some expansion of the thymus, with extensive invasion of
the liver in some cases and occasional involvement of the
peripheral lymph nodes and Peyer’s patches (Figure 5A and B).
The tumour pathology was noted as either lymphosarcoma
(lymphoma) or neoplastic cells resembling histiocytes (histiocytic
sarcoma) (Figure 5D). Splenic tumours of mice of line 127
analysed by flow cytometry were found to be of B-cell origin,
staining positive for the B-cell specific surface marker B220 and
negative for the T-cell surface marker CD3 (Figure 5E). In
addition, some tumours showed clonal IgH gene rearrangements
(supplementary Figure S4).
IL-10 secretion was examined by ELISA but not detected in
serum samples from five line 127 tumour bearing mice or five
NSC serum samples (all samples showing no IL-10 compared to a
positive standard curve, thus there is no graphical data to show).
Analysis by cytokine array showed a negligible signal for IL-10 and
IL-9 in a pool of three splenic tumour tissue samples, which was
equivalent to NSC splenic samples. Therefore there is no evidence
to suggest that EBER1 is acting to induce levels of IL-10, either in
the serum or tumours in these mice.
Does EBER1 Cooperate with Myc in Lymphomagenesis In
Vivo
In oncogene-carrying transgenic cross breeds, reduced tumour
latency in bitransgenic animals can indicate that the two
oncogenes act with functionally different consequences, while no
cooperation can (but not necessarily) suggest that the two
Figure 4. Steady state phosphorylated and total PKR and eIF2a levels in the EBER1 mice. Steady state PKR (68 kD) and eIF2a (40 kD)
levels, along with their activated phosphorylated forms (as indicated) were assessed by western blotting (for PKR: 7.5% SDS-PAGE, for eIF2a: (10%
SDS-PAGE). Protein extracts from three biological replicates from the highest expressing tissues from each of three lines were examined: thymus from
EmEBER1 line 137, Peyer’s patches from EmEBER1 line 127 and spleen from EmEBER1 line 134 along with NSC replicates for each tissue. The human BL
cell line BJAB (B) treated with IFNa has been used as a positive control. Detected protein levels were quantified and normalised against b-tubulin
(55 kD) levels or for Peyer’s patches* against GAPDH (37 kD) levels. Note: a 40 kD band for eIF2a could not be detected in Peyer’s patch tissues (even
after long exposure as shown in the inset panel for eIF2a Peyer’s patch samples), however the a-eIF2a antisera did react with a band of approximately
33 kD which was also detected by the a-phospho-eIF2a antisera (the former only, also reacting with a murine band at 43 kD), which could be a tissue
specific derivative of eIF2a. Molecular weight markers are shown to the left.
doi:10.1371/journal.pone.0009092.g004
EBER1 Transgenic Mice
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oncogenes may employ functionally redundant mechanisms, even
if the mode of action is highly divergent. In order to explore this
with the tumour prone EBER1 line 127, the mice were cross bred
with the well characterised Emc-myc and EmN-myc lines of mice
[31,32]. Tumours arising in the bitransgenic mice phenotypically
resembled those arising in the Myc mice with extensive
involvement of the lymph nodes (Figure 5A and B). No
acceleration to tumour onset was observed between EmE-
BER1.127 and Emc-myc mice (Figure 6A). While bitransgenic
mice in the EmEBER1.127 and EmN-myc cross on average
showed a reduced latency to tumour onset compared to EmN-
myc mice (median of 214 days compared to 406 days, Figure 6B),
the survival curves were not found to be statistically significantly
different. While these data do not demonstrate cooperative action
between Myc and EBER1 in lymphomagenesis, they do not
disprove the possibility. Similarly, no cooperative action in
tumour latency between EBER1 and the viral nuclear antigen
EBNA-1 was revealed by this approach (Figure 6C).
In order to explore this further, Myc expression and activity in
the EBER1 tumours was examined. Again, if EBER1 function was
redundant with Myc, one would not expect induction of Myc to
serve any selective advantage in the process of tumourigenesis and
therefore would not expect to detect induced expression in the
ensuing tumour. Alternatively, if EBER1 acted through induction
of Myc, constitutive Myc expression would be observed. Induction
of c-Myc expression was observed in several, but not all, of the
EmEBER1.127 lymphomas (Figure 7). Furthermore, activation of
E-box DNA binding (to which Myc family proteins bind) was also
observed in EBER1 tumour samples (Figure 7C), even in the
absence of detection of c-Myc or N-Myc (Figure 7, note tumour
sample 127.49). These data indicate that the function of EBER1 in
tumourigenesis is neither redundant with Myc nor acts through
induction of Myc, but may be cooperative.
Discussion
This report describes expression of a pol III transcribed
transgene displayed by several lines of mice which, in some lines,
is restricted or biased to the lymphoid compartment. Despite the
low level of EBER1 expression achieved in these transgenic mice a
phenotype of lymphoid organ enlargement, notably splenomegaly,
was evident in several independent lines with progression to late
onset lymphoma, particularly apparent in line 127 with highest
EBER1 expression. These data provide the first evidence that a
pol III non-coding RNA has oncogenic potential in vivo and could
implicate EBER1 in the initiation or progression of EBV
associated malignant disease.
To explore the mode of action of EBER1 as an oncogene, cross-
breeding studies were undertaken. EBER1 and EBNA1 do not
appear to cooperate in reducing the latency to lymphomagenesis
in this system, nor do EBER1 and Myc. Thus the function of
EBER1 as a predisposing factor in tumourigenesis cannot be
classified by this approach. However, c-Myc induced expression
and DNA binding activity was detected in several EBER1
tumours. This does not imply that EBER1 induces Myc, indeed
the differing levels of Myc in the tumour samples (in some cases
Myc is not detected) would argue against this. Instead this suggests
that Myc has been induced or activated in some instances (for
example by mutation or epigenetic modification) during the
progressive steps to tumourigenesis and has thereby contributed to
the development of the lymphoma. This function would not be
selected for in tumour development if the action of Myc was
Table 1. Summary of the lymphoid pathology in EmEBER1 lines.
Tg Line
Age (mo)
127 131 132 134 135 136 137 138 142 145
negative
sibling control
.19 – #24 16 (13)/24 7 (4)/11 1 (1)/6 7 (3)/9 4 (2)/4 4(2)/8 3 (2)/10 1 (1)/4 5 (1)/9 6 (4)/13 30 (6)/122
.14 - #19 7 (7)/8 K 3/4 K 1/2 0/1 0/3 3 (3)/24
.10 – #14 3 (2)/5 1 (1)/4 2/3 0/4 0/3 0/3 3/5 0/4 3 (2)/33
.6 – #10 14 (3)/18 0/5 0/3 0/9 1/1 5/16 14 (2)/21 1/12 0/7 2/8 2/66
.3 – #6 2/15 0/13 0/2 2/2 0/1 0/3 5/12 0/8 1/2 0/20 0/151
# 3 4/6 0/2 0/1 0/1 3/3 0/1 0/3 0/51
Total 46/76 9/37 3/14 9/25 8/11 12/33 22/48 6/32 6/19 8/51 38/447
Percentage 60.5 24.3 21.4 36 72.7 36.4 45.8 18.8 31.6 15.7 8.5
P x2 ,0.001 ,0.025 ,0.1 ,0.001 ,0.001 ,0.001 ,0.001 ,0.0525 ,0.001 ,0.1
Analysis of
.19 – #24 16 (13)/24 7 (4)/11 1 (1)/6 7 (3)/9 4 (2)/4 4 (2)/8 3 (2)/10 1 (1)/4 5 (1)/9 6 (4)/13 30 (6)/122
Percentage 66.7 63.6 16.7 77.8 100 50 30 25 55.6 46.2 24.6
P x2 ,0.001 ,0.001 ,0.9 ,0.001 ,0.001 ,0.05 ,0.5 ,0.8 ,0.02 ,0.05
Analysis of
.10 - #24 26 (22)/37 9 (5)/17 3 (1)/9 7 (4)/13 7 (2)/8 4 (2)/11 4 (2)/15 5 (1)/11 5 (1)/10 6 (4)/20 36 (11)/179
Percentage 70.3 52.9 33.3 53.8 87.5 36.4 26.7 45.5 50 30 20.1
P x2 ,0.001 ,0.01 ,0.8 ,0.01 ,0.001 ,0.2 ,0.9 ,0.05 ,0.05 ,0.3
The number of transgenic positive animals which have either developed lymphoma or shown signs of lymphoid expansion, out of the total number of animals
examined in the different age categories are shown (number with lymphoid pathology (bold: of which were neoplastic)/total number of mice in the category). The
majority of negative mice examined in the 19-24 months category were taken at 23/24 months at the end of study. Generally mice examined under 1 year old were
taken in cohort groups (without phenotypic selection) for particular studies (eg. expression analysis). The percentage of mice with tumour-expansion compared to no
tumour is indicated for each line. The P values were calculated from a chi squared (P x2) test. To avoid bias due to the large number of negative sibling control mice
taken under the age 10 months, largely phenotype free, the percentage of mice with lymphoid expansion and chi squared tests are also shown for the older age groups
alone (.10#24 months and .19#24 months, in the panels below).
doi:10.1371/journal.pone.0009092.t001
EBER1 Transgenic Mice
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Figure 5. The lymphoma phenotype of Em78EBER1 line 127 mice. The lymphoma phenotype observed in a transgenic Em78EBER1 line 127
mouse (127) and a 127xEmNmyc bitransgenic mouse compared to a NSC mouse, seen in the spleen (A) and lymph nodes (LN) (B). The 127
transgenic mesenteric lymph node shown was a portion of a large interconnected series of nodes. (C) Kaplan Meier plot of line 127 Em78EBER1
transgenic mice (127 EBER1) (red, n = 33) and NSC (blue, n = 151) mice comparing lymphoma incidence, log rank t test p,0.0001. The study end
point was 2 years. (D) Photomicrographs of H&E stained sections of Em78EBER1 line 127 tumours taken at original magnification 400x (scale bar
shown). Several mitotic Figures are labelled with arrows. Note: lymphosarcoma 127.37 revealed IgH gene rearrangements (supplementary
information) and histiocytic sarcoma 127.51 showed B220 staining (seen in panel E), but no detectable IgH rearrangements. (E) Flow cytometry of a
127 splenic tumour (right) and NSC spleen (left) staining with the T-cell and B-cell specific markers, CD3 and B220 respectively. B- and T-cell
quadrant percentages are shown.
doi:10.1371/journal.pone.0009092.g005
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redundant with that of EBER1 (the latter activity already being
present in the EBER1 expressing tissues) and as such the data
indicate that Myc and EBER1 action are not redundant in
tumourigenesis and potentially could cooperate in ways not
assessed by the tumour latency assay described.
In BL cell lines EBER expression has been shown to lead to
increased expression of the immunosuppressive cytokine IL10
[20]. Thus EBER1 might play a role in permitting the survival of
an infected cell through disruption of the immune system. This is
supported by the observation that EBER1 inhibits IFN-a
induced apoptosis, which has been proposed (though controver-
sial) to act via the binding and inhibition of PKR auto-
phosphorylation [11,12]. PKR, which inhibits protein synthesis
through the phosphorylation of eIF2a, has been suggested to
have tumour suppressor properties since a functionally defective
PKR has been shown to enhance transformation and tumour-
igenesis of NIH3T3 cells [33,34]. In our studies, we could not
detect any induction of IL-10 or inhibition by EBER1 of steady
state levels of phosphorylated PKR or its substrate eIF2a in vivo,
as was also noted by Ruf et al. in BL cells [12]. However, it
remains possible that EBER1 expression could influence IL-10
levels or PKR activation following immune challenge. Further-
more, EBER1 expression in these mice is low and very high
levels of EBER1 may be required to detect disruption of PKR
activity. Nevertheless, this raises the possibility that EBER1 is not
acting through these routes to induce the observed phenotype.
EBER1 might regulate cell survival or growth through
modulation or sequestration of its protein partners. Alternatively
it might directly regulate gene expression as a small RNA. Small
non-coding RNAs, particularly miRNAs represent a class of post-
transcriptional regulatory molecules which have diverse functions,
including the control of cell growth [35]. Indeed miR155 has been
shown to lead to lymphoma in transgenic mice [36] and the EBV
encoded miRNA BHRF1-3 appears to suppress an anti-tumour,
Figure 6. Latency to lymphoma in EBER1 mice compared to EBER1/Myc and EBER1/EBNA-1 bitransgenic mice. Kaplan Meier plots for
lymphoma incidence from cross breeds of EmEBER1.127 with Emc-myc (A), or EmN-myc (B) or EmEBNA-1 (of the line 26) (C) mice are shown.
Bitransgenic mice in each case are shown with the open box symbol. (A) Study end point: 500 days, log rank t test P = 0.2803. (B) Study end point:
740 days, log rank t test P = 0.1308. (C) Study end point: 500 days, log rank t test P = 0.263. These data show no significant difference in the lymphoma
incidence curves between EmMyc or EmEBNA-1 single transgenic compared with the relevant bitransgenic mice.
doi:10.1371/journal.pone.0009092.g006
EBER1 Transgenic Mice
PLoS ONE | www.plosone.org 8 February 2010 | Volume 5 | Issue 2 | e9092
T-cell-attracting chemokine, CXCL-11 [2]. Twenty two miRNAs
expressed by EBV have been identified, none of which incorporate
EBER sequences [37–39]. Moreover, there is no evidence to
indicate that EBER1 is processed by Dicer [40] to form a miRNA
and it does not bind to exportin 5 [13]. However, it cannot be
ruled out that EBER1 might be processed and act in an as yet
undefined way.
While EBER1 levels are often very high in BL cell lines and
EBV positive lymphoblastoid cell lines, the relative levels can vary
enormously, for example EBER1 levels are 100 fold higher in the
BL cell line Raji compared to Akata and it is not clear how this
compares to the levels that were expressed in the primary tumour
cells. The expression level achieved in the transgenic mice in this
study is low, nevertheless it is sufficient to have induced an altered
Figure 7. Analysis of Myc expression and DNA binding activity in transgenic lymphomas. (A and B) Western blots of 100mg protein
extracts from tumours samples from spleen or lymph node (LN) tissues, from EmEBER1 line127, or Emc-myc or EmEBER line 127 crossed with EmN-myc
mice are shown, probed with antibodies to c-Myc, 67 kD (A) or N-myc, 67 kD (also detecting another antibody specific band at 120 kD) (B). Sample
loading was assessed by Ponceau staining of the blot (lower panel A) or from non-specific band staining (lower panel B). (C) EMSA for E-box binding
activity of nuclear extracts of tumour samples from mice of EmEBER1 line 127 (127.37 and 127.49), a bi-transgenic EmEBER1/EmN-Myc (N127.29), an
EmN-Myc (N127.41) and Emc-myc (c1005) and non tumour NSC (as indicated above the tracks. All samples were assayed with an E-box oligo and a
track with free oligo/probe is indicated by ‘‘O’’. The addition of 100 x unlabelled competitor to a sample is indicated by (+). The specific bands are
indicated.
doi:10.1371/journal.pone.0009092.g007
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phenotype. As such, these mice provide a means to study the
mechanism of action of this small RNA in vivo, both its impact
upon immune function and its role in tumourigenesis.
Materials and Methods
Ethics Statement
All procedures were conducted according to UKCCCR
Guidelines for the Welfare of Animals in Experimental Neoplasia
and under UK Home Office license and the research has complied
with Home Office and institutional guidelines and policies.
Construction of Plasmids
EBER1 plasmid pLEXIII [30] was used as a PCR template to
generate 323EBER1, 78EBER1 and 39EBER1 (differing in
promoter length) using primers CR1, CR2, or CR3 forward
primers with CR4 reverse primer (all primer sequences can be
found in supplementary Tables S2 and S3), 30 cycles, annealing at
60uC. The EcoRI-XhoI digested PCR products were ligated to
pcDNA-Em vector (Em is the murine immunoglobulin heavy chain
(IgH) intronic enhancer and its sequence was derived from
pEmLMP1 [41]) to generate pEm323EBER1, pEm78EBER1 and
pEm39EBER1 plasmids.
EBER1 Transgenic Mice Generation, Genotyping and
Cross-Breeding
XbaI linear fragments from pEm323EBER1, pEm78EBER1 and
pEm39EBER1 were used as transgenes for pronuclear microinjec-
tion of B6D2F2 zygotes as described previously [41]. Genotyping
of founders was performed by Southern blotting as described
previously [41] using a radiolabelled CR1-CR4 PCR product
probe fragment. Genotyping of subsequent offspring was per-
formed by PCR with CR8 and CR4 primers, 25 cycles, annealing
at 50oC. Transgenic founders were bred to C57Bl/6 strain to
establish lines. Transgene copy number was estimated from 1st
generation offspring by slot blot signal intensity by Bas-1500
PhosphorImager and MacBas V2.2 software. Transgenic mice
were compared in the assays to transgene-negative sibling controls
(NSC), being genetically identical (with the soul exception of the
transgene) and housed together.
EmEBER1 mice were cross-bred with EmEBNA-1 [42], Emc-
myc [31] and EmN-myc mice [32]. Mice were genotyped by
Southern blotting [41] and for transgenic c-myc by PCR using c-
mycF and c-mycR primers (supplementary Table S2) using 12
cycles, annealing 64uC followed by 25 cycles, annealing 58uC.
EmEBNA-1 and Emc-myc mice were maintained in the C57Bl/6
strain. EmN-myc mice were maintained in the Balb/c strain, thus
cross-bred sibling cohorts studied with this latter line were all F1
for the two strains and internally controlled.
Phenotype Monitoring and Pathology
Sibling cohorts of mice were monitored for phenotype for up to
2 years. In addition, the phenotype of mice used in expression and
other studies was noted. Kaplan-Meier plots were generated on
the basis of lymphoma development, statistical analysis was
performed using GraphPad Prism4 software using a log rank t
test with p#0.05 considered to be statistically significant. For the
proportion of transgenic mice with hyperplasia and lymphoma
compared to negative mice, the statistical analysis was performed
using a Chi squared test. Tissues including thymus, spleen, lymph
nodes and liver were fixed in 10% neutral buffered formalin,
dehydrated in ethanol, embedded in paraffin wax, sectioned at 3–
5 mm thickness and stained with haematoxylin and eosin for
histological examination.
RNA Extraction, RT-PCR and Quantitative RT-PCR
Total tissue RNA was extracted as described [41]. The RNA was
DNase I treated (Promega) followed by acid phenol-chloroform
extraction and precipitation. RNA (5 to 10mg) was used as template
for the reverse-transcriptase (RT) reaction using an EBER1 gene
specific reverse primer (CR4) or oligo-dT (reverse-it cDNA
synthesis kit, ABgene) and MMLV RT enzyme (Invitrogen). Each
reaction was performed in duplicate with or without RT enzyme.
One quarter of the RT reaction was used as template for PCR
using either CR8 or CR25 forward primers with CR9 reverse
primer for 25 to 30 cycles annealing at 40uC. The products were
separated by gel-electrophoresis, Southern blotted, probed with a
radiolabelled CR1-CR4 probe and analysed by PhosphorImagery
for a semi-quantitative determination. Quality of RNA was
confirmed by gel electrophoresis and comparative quantities by
RT-PCR with oligodT and GAPDH specific primers. For
quantitative RT-PCR, the PCR reaction was conducted using the
Absolute SYBR Green Rox mix kit (ABgene) according to
manufacturers instructions and analysed with the DNA engine
OpticonTM software (MJ Research). A standard curve was obtained
using a known concentration of EBER1 plasmid DNA as template.
Western Blotting
Proteins were extracted by polytron disruption of snap frozen
samples in high salt buffer [20mM Hepes pH 7.9, 0.4M NaCl,
1mM EDTA pH 8, 1mM EGTA pH 8, 1mM DTT, 1mM PMSF,
phosphatase inhibitors and protease inhibitors (Sigma)] and
incubated for 10 minutes at 4uC. Following centrifugation, protein
concentration was determined using the Bradford assay. Protein
samples (100mg) were separated by 7.5% SDS-PAGE and western
blotted as previously described [43]. Primary antibodies used were
directed against the following proteins: c-Myc, N-Myc, b-tubulin,
eIF2a, phospho-eIF2a (ser51), PKR and phospho(thr446)-PKR
(supplementary Table S4); at 1/1000 in blocking buffer (PBST
[PBS, 0.1% (v/v) Tween-20] with 5% (w/v) non-fat milk powder).
Secondary goat anti-rabbit IgG horseradish peroxidase conjugated
antibody was used. Detection was performed using ECL+ kit (GE
Healthcare) following the manufacturer’s instruction. Western
blots for reprobing were stripped of antibody by agitation at 50uC
for 1 hour in 2% SDS, 62.5 mM Tris pH 6.8, 100 mM 2
bmercaptoethanol and washed twice in PBST for 10 minutes.
Densitometry of autoradiograph bands was carried out using
appropriately low exposure films with the Kodak 1D software on
imported images.
Electrophoretic Mobility Shift Assay
Protein extracts were prepared as described above and assayed
as previously detailed [44]. A Myc-binding E-box containing
double-stranded oligonucleotide (supplementary Table S3) was end
labelled with 32PdCTP. The probe was purified using NICKTM
Columns (Amersham). For each sample, two reactions were set up:
10mg of protein extract was added to 1mg of poly dIdC (Sigma) in
binding buffer [10 mM Tris, pH 7.5, 50 mM NaCl, 1 mM DTT,
1 mM EDTA and 5% glycerol]. To the duplicate, 200x of cold
competitor (unlabelled oligonucleotide) was added and the samples
were incubated on ice for 10 minutes. Probe (0.5 ng) was added to
each sample and incubated for 20 minutes on ice. The reaction
products were electrophoresed through 6% non-denaturing
acrylamide gels, which were dried and exposed to film.
Flow Cytometry and Cell Selection
Cells were isolated from spleen, thymus, peripheral and
mesenteric lymph nodes (PLNs and MLNs) and bone marrow.
EBER1 Transgenic Mice
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Erythrocyte exclusion was performed with NH4Cl for 10 minutes
to lyse the red blood cells, except for PLNs and MLNs. The cells
were washed and resuspended in PBS. 106 cells were stained with
the antibodies indicated (supplementary Table S5) for 45 minutes
at 4uC. Following two PBS washes, cells were fixed in 0.1%
formaldehyde overnight before being analysed using a FACSca-
libur flow cytometer (Beckton Dickinson). Data were collected and
analysed using CellQuest software. For B-cell/T-cell separation,
cells were isolated from spleen and Peyer’s patches (pooling
samples from different mice as required). T-cells were first selected
using Thy1.2 dynabeads (Dynal). The flow through was then used
for B-cell selection with B220 dynabeads, typically achieving 90%
purity in each case (assessed by flow cytometry).
Enzyme-Linked Immunosorbant Assay (ELISA)
Serum samples were assayed at 1/20 dilution for murine
interleukin-10 (IL-10) by ELISA (Biolegend #431404S) according
to the manufacturer’s protocol. Briefly, 96 well plates were coated
with capture antibody overnight at 4uC and then blocked with
assay diluent. Samples in duplicate or triplicate and standards
were incubated in the wells overnight at 4uC. IL-10 was detected
with a biotin-conjugated detection antibody, followed by avidin-
HRP and then HRP substrate. Multiple well washes were
conducted between each step. Plates were read at 450 nm. Tissue
samples were assessed for IL-10 and IL-9 levels as part of a
cytokine array (Raybiotech) according to manufacturer’s protocol.
Supporting Information
Figure S1 Comparative EBER1 transgene expression is shown
for Peyer’s patches and thymus tissues and compared to the EBV
positive BL cell line Akata (AK2003) and the EBV negative
derivative of this cell line Akata negative-31 (AK31). Quantitative
RT-PCR was conducted using DNase treated RNA from the cell
lines and tissues. The RT reaction for EBER1 was conducted
using gene specific primer CR4 and for GAPDH using oligodT,
using 5 mg of total RNA. An RT minus and plus reaction was
performed for each sample. Q-RT-PCR was conducted using 1/4
of the sample, using primers CR8 and CR9 for EBER1 or forward
and reverse primers for GAPDH (Table S2 of this supplementary
information). The Q-RT-PCR data are shown in (A) and the
relative expression levels (arbitrary units), normalised to GAPDH
are shown for each graph (i to iv) in (B). The difference between
the levels of EBER1 in the Akata cell line compared to the
transgenic tissues is so great it necessitated dilution of the Akata
sample by 50 fold to gain comparison. Using GAPDH as an
internal control allows direct, normalised comparison between
similar tissues (for example, comparing murine thymuses), but this
is less accurate when comparing different tissues to one another.
Between different cell types and tissues and certainly different
species, it would be expected that house keeping genes (such as
GAPDH) are expressed at different relative levels and as such
cannot serve as normalising controls between tissues or to other
species cell lines. As such, a normalised comparison of expression
levels between the mouse tissues (which might be expected to
contain cells not expressing EBER1) and the clonal human cell line
is not possible, however, by direct comparison the amount of
EBER1 cDNA in the diluted Akata sample is 100 fold higher than
the highest EBER1 thymus sample (that of line 142).
Found at: doi:10.1371/journal.pone.0009092.s001 (0.23 MB PPT)
Figure S2 Transgene expression in non-lymphoid tissues was
assessed in lines 136, 127, 131 and 137 from DNaseI-treated, total
RNA derived from tissues of 2 to 4 month old mice by RT-PCR
using a gene specific RT primer. PCR products were Southern
blotted and hybridised with an EBER1 probe. +indicates inclusion
of RT, - indicates no RT added and is indicative of signal from
any residual DNA in the sample. PCR controls: negative (N) water
only, positive (P) amplified from plasmid DNA. Tissues include:
stomach, lung, heart, small intestine (S.int), testis, ovaries, uterus,
kidney (kid), oesophagus (oesp), trachea, brain, tongue, salivary
gland (SG), nasopharyngeal region (NPR), muscle and ears. Note:
to detect very low levels of expression, exposure times were
maximised, such that in some cases, a low signal (presumably from
tiny amounts of contaminating DNA) can be detected in RT-
samples. Thus where RT- and RT+ samples show a band of
similar intensity, this would imply no detectable expression in that
tissue.
Found at: doi:10.1371/journal.pone.0009092.s002 (1.49 MB PPT)
Figure S3 Flow cytometric analysis of surface markers of pre-
phenotypic lymphoid tissues of EmEBER1 transgenic mice. The
lymphoid tissues (spleen, thymus, peripheral and mesenteric lymph
nodes and bone marrow) were examined by flow cytometry from
young mice (2–4 months old) of the lines 127 (shown) and 131 (not
shown), prior to the development of phenotype. No difference
between transgenic and NSC tissues were found for fluorochrome-
conjugated antibody staining against B220, CD5, CD23, CD43,
IgM, IgG, IgA, CD3, Thy1.2, CD2, CD4 and CD8, except for
B220/CD5 staining of Peyer’s patch cells of mice of line 127 as
shown in the representative examples described. First panel a - c:
Spleen, bone marrow and Peyer’s patches were collected from
three line 127 mice (right) and 3 NSC (left) and each pooled. 106
cells were stained with anti-B220/FITC, CD3/PE (a), B220/
FITC, Thy1.2/PE (b) and B220/FITC, CD3/PE (c), all showing
no difference between transgenic and NSC. The percentage of
cells in each quadrant is indicated. Second panel d - f: Peyer’s
patches stained with anti-CD5/FITC, CD3/PE (d), CD5/FITC,
B220/PE (e) are shown. The forward (FSC) and side scatter (SSC)
for the CD5/FITC, B220/PE stain is shown in f. The percentage
of cells in each quadrant is indicated. While no difference was
observed in the CD5+/CD3+ T-cell population (d), the CD5+ B-
cell population is largely B220low in the NSC samples while it is
B220neg in the transgenic sample (e), suggesting the B1a
population might be increased in this tissue in the transgenic line.
This is supported by the increase in large, granular cells (f).
Repetition of the experiment with further mice gave the same
result.
Found at: doi:10.1371/journal.pone.0009092.s003 (0.12 MB PPT)
Figure S4 Immunoglubulin heavy chain gene (IgH) rearrange-
ment in the EBER1 tumour samples were assessed by Southern
blotting of EcoRI digested genomic DNA. DNA derived from
tumour tissues of an EmN-myc mouse (positive control), two
EmEBER1 line 127 mice (127.49 and 127.37) and NSC mouse
were examined. The membrane was hybridised with an IgH J-
region sequence probe showing rearrangements (circles to left of
track) compared to the endogenous germ line band (E). S = spleen,
MLN=mesenteric lymph node. The clonal IgH rearrangements
detected in the EBER tumour samples, like that of the N-myc
tumour sample suggests that the tumours are of B-cell origin,
supporting the flow cytometry data.
Found at: doi:10.1371/journal.pone.0009092.s004 (0.15 MB PPT)
Table S1 Numbers of founder mice developed with the three
EBER1 construct variants are shown with the number of
transgenic lines successfully generated from these. Of the eleven
lines tested for expression, ten showed expression while one (line
Em39EBER1.133) showed no expression in any tissue tested. The
ID of the expressing lines is given with the integrated transgene
copy number indicated in parentheses.
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Found at: doi:10.1371/journal.pone.0009092.s005 (0.03 MB PPT)
Table S2 Oligonucleotide sequences used for PCR.
Found at: doi:10.1371/journal.pone.0009092.s006 (0.05 MB
PDF)
Table S3 Oligonucleotide sequences used for EMSA.
Found at: doi:10.1371/journal.pone.0009092.s007 (0.07 MB
PDF)
Table S4 Antibodies used in western analyses.
Found at: doi:10.1371/journal.pone.0009092.s008 (0.05 MB PPT)
Table S5 Antibodies used for flow cytometry.
Found at: doi:10.1371/journal.pone.0009092.s009 (0.03 MB PPT)
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